TSRX

Trius Therapeutics Inc

A developer of antibiotics for serious infections, this San Diego biopharmaceutical company's flagship medicine was tedizolid phosphate, a drug meant to fight hard-to-treat bacteria such as MRSA. Founded in 2004 as Rx3 Pharmaceuticals — a nod to the pharmacy shorthand Rx — it later took the name Trius Therapeutics. The compound itself was first created by South Korea's Dong-A Pharmaceutical, and in 2013 Cubist Pharmaceuticals bought Trius and later sold the medicine under the brand name Sivextro.

Recent Activity

Show $

2013Q3

1 sell

First Eagle Investment ManagementEXIT

-1.67M shares

First Eagle Investment ManagementEXIT

-1.67M shares

2013Q2

1 sell

First Eagle Investment ManagementTRIM

-122.3K shares(-6.8%)

First Eagle Investment ManagementTRIM

-122.3K shares(-6.8%)

2013Q1

1 buy

First Eagle Investment ManagementADD

+736.6K shares(+69.6%)

First Eagle Investment ManagementADD

+736.6K shares(+69.6%)

Loading more activity...